Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3b study of subcutaneous tocilizumab in active rheumatoid arthritis after inadequate response to non-biologic DMARDs or first anti-TNF therapy
2013-000054-22Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Change in DAS28-ESR. Started Aug 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-000054-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000054-22.